Search

Your search keyword '"Schultz, Ellen M"' showing total 15 results
Start Over Author "Schultz, Ellen M"
15 results on '"Schultz, Ellen M"'

1. The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021—December 2022

Author

Fiebelkorn, Amy Parker, Adelsberg, Sara, Anthony, Rishelle, Ashenafi, Samrawit, Asif, Amimah F., Azzarelli, Maria, Bailey, Theresa, Boddie, Timothy Tee, Boyer, Alaina P., Bungum, Nicole Williams, Burstin, Helen, Burton, Jacqueline L., Casey, David M., Chaumont Menendez, Cammie, Courtot, Brigette, Cronin, Kelly, Dowdell, Cherrie, Downey, Laura H., Fields, Megan, Fitzsimmons, Tom, Frank, Alexa, Gustafson, Emily, Gutierrez-Nkomo, Margaret, Harris, Benita L., Hill, Joanna, Holmes, Kathleen, Huerta Migus, Laura, Jacob Kuttothara, Joanna, Johns, Natalie, Johnson, Jennifer, Kelsey, Alice, Kingangi, Lucy, Landrum, Cynthia M., Lee, James T., Martinez, Pedro D., Medina Martínez, Gisela, Nicholls, Richard, Nilson, Jane R., Ohiaeri, Nma, Pegram, Laura, Perkins, Claire, Piasecki, Alexandra M., Pindyck, Talia, Price, Sarah, Rodgers, Michelle S., Roney, Heather, Schultz, Ellen M., Sobczyk, Elizabeth, Thierry, JoAnn M., Toledo, Chelsea, Weiss, Nancy E., Wiatr-Rodriguez, Amy, Williams, Lauren, Yang, Chenmua, Yao, Andrea, and Zajac, Julie

Published
2024
Full Text
View/download PDF

8. Brief Report: Variation in Experts’ Beliefs about Lung Cancer Growth, Progression and Prognosis

Author

Schultz, Ellen M., Silvestri, Gerard A., and Gould, Michael K.

Subjects
Survival Rate, Lung Neoplasms, Delphi Technique, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Outcome Assessment, Health Care, Practice Guidelines as Topic, Disease Progression, Humans, Solitary Pulmonary Nodule, Clinical Competence, Prognosis, Article
Abstract

Little is known about the natural history of malignant solitary pulmonary nodules (SPN). Experts' beliefs may help fill these knowledge gaps and explain variation in clinical practices.Using a modified Delphi process, we surveyed a group of lung cancer experts about tumor growth, disease progression, and prognosis in patients with malignant SPN. After completing the first survey, experts were given the opportunity during a second survey to revise their responses in light of their peers' beliefs.The response rate was 100% (14 of 14) for both surveys. There was consensus that disease progression depends on the tumor growth rate, that survival for patients with untreated lung cancer is approximated by a declining exponential function, and that treatment is delayed by approximately 1 tumor volume doubling time (TVDT) in patients who undergo a period of "watchful waiting." Just over half of experts (8 of 14) agreed that lung cancer progresses in three steps (from local to regional to distant disease), whereas 43% (6 of 14) preferred a 2-step model (from local to systemic disease). Likewise, 64% of experts (9 of 14) believed that malignant nodules grow exponentially, whereas 36% (5 of 14) believed that growth is slower than exponential. Experts' estimates of the risk of disease progression during a period of observation lasting 1 TVDT varied from 1 to 50%. Estimates of 5-year survival for patients in whom diagnosis and treatment were delayed by 1 TVDT varied between 40% and 80%.There is substantial variability in experts' beliefs about the natural history of untreated, malignant SPN. Different beliefs may be partly responsible for variation in management practices.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results